Angela Huttner1, Selidji Todagbe Agnandji2, Christophe Combescure3, José F Fernandes4, Emmanuel Bache Bache4, Lumeka Kabwende4, Francis Maina Ndungu5, Jessica Brosnahan2, Thomas P Monath6, Barbara Lemaître7, Stéphane Grillet7, Miriam Botto8, Olivier Engler9, Jasmine Portmann9, Denise Siegrist9, Philip Bejon5, Peter Silvera8, Peter Kremsner2, Claire-Anne Siegrist10. 1. Division of Infectious Diseases, University Hospitals of Geneva, Geneva, Switzerland; Infection Control Programme, University Hospitals of Geneva, Geneva, Switzerland; Centre for Vaccinology, University Hospitals of Geneva, Geneva, Switzerland. 2. Centre de Recherches Médicales de Lambaréné, Hôpital Albert Schweitzer, Lambaréné, Gabon; Institut für Tropenmedizin and German Centre for Infection Research (DZIF) partner sites, Universitätsklinikum Tübingen, Tübingen, Germany. 3. Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland. 4. Centre de Recherches Médicales de Lambaréné, Hôpital Albert Schweitzer, Lambaréné, Gabon. 5. KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. 6. NewLink Genetics Corporation, Devens, MA, USA. 7. Centre for Vaccinology, University Hospitals of Geneva, Geneva, Switzerland. 8. Non-clinical Development, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA. 9. Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerland. 10. Centre for Vaccinology, University Hospitals of Geneva, Geneva, Switzerland. Electronic address: claire-anne.siegrist@unige.ch.
Abstract
BACKGROUND: The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, but duration of immunity is unknown. We aimed to assess antibody persistence at 1 and 2 years in volunteers who received single-dose rVSV-ZEBOV in three previous trials. METHODS: In this observational cohort study, we prospectively followed-up participants from the African and European phase 1 rVSV-ZEBOV trials, who were vaccinated once in 2014-15 with 300 000 (low dose) or 10-50 million (high dose) plaque-forming units (pfu) of rVSV-ZEBOV vaccine to assess ZEBOV glycoprotein (IgG) antibody persistence. The primary outcome was ZEBOV glycoprotein-specific IgG geometric mean concentrations (GMCs) measured yearly by ELISA compared with 1 month (ie, 28 days) after immunisation. We report GMCs up to 2 years (Geneva, Switzerland, including neutralising antibodies up to 6 months) and 1 year (Lambaréné, Gabon; Kilifi, Kenya) after vaccination and factors associated with higher antibody persistence beyond 6 months, according to multivariable analyses. Trials and the observational study were registered at ClinicalTrials.gov (Geneva: NCT02287480 and NCT02933931; Kilifi: NCT02296983) and the Pan-African Clinical Trials Registry (Lambaréné PACTR201411000919191). FINDINGS: Of 217 vaccinees from the original studies (102 from the Geneva study, 75 from the Lambaréné study, and 40 from the Kilifi study), 197 returned and provided samples at 1 year (95 from the Geneva study, 63 from the Lambaréné, and 39 from the Kilifi study) and 90 at 2 years (all from the Geneva study). In the Geneva group, 44 (100%) of 44 participants who had been given a high dose (ie, 10-50 million pfu) of vaccine and who were seropositive at day 28 remained seropositive at 2 years, whereas 33 (89%) of 37 who had been given the low dose (ie, 300 000 pfu) remained seropositive for 2 years (p=0·042). In participants who had received a high dose, ZEBOV glycoprotein IgG GMCs decreased significantly between their peak (at 1-3 months) and month 6 after vaccination in Geneva (p<0·0001) and Lambaréné (p=0·0298) but not in Kilifi (p=0·5833) and subsequently remained stable at all sites apart from Geneva, where GMC in those given a high dose of vaccine increased significantly between 6 months and 1 year (p=0·0264). Antibody persistence was similar at 1 year and at 6 months in those who had received a low dose of vaccine, with lower titres among participants from the Geneva study at 2 years than at 1 year after vaccination (GMC ratio 0·61, 95% CI 0·49-0·77; p<0·0001). In multivariable analyses, predictors of increased IgG GMCs beyond 6 months included high-dose versus low-dose vaccination (Geneva p=0·0133; Lambaréné p=0·008) and vaccine-related arthritis (p=0·0176), but not sex, age, or baseline seropositivity (all p>0·05). Neutralising antibodies seem to be less durable, with seropositivity dropping from 64-71% at 28 days to 27-31% at 6 months in participants from the Geneva study. INTERPRETATION: Antibody responses to single-dose rVSV-ZEBOV vaccination are sustained across dose ranges and settings, a key criterion in countries where booster vaccinations would be impractical. FUNDING: The Wellcome Trust and Innovative Medicines Initiative 2 Joint Undertaking.
BACKGROUND: The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, but duration of immunity is unknown. We aimed to assess antibody persistence at 1 and 2 years in volunteers who received single-dose rVSV-ZEBOV in three previous trials. METHODS: In this observational cohort study, we prospectively followed-up participants from the African and European phase 1 rVSV-ZEBOV trials, who were vaccinated once in 2014-15 with 300 000 (low dose) or 10-50 million (high dose) plaque-forming units (pfu) of rVSV-ZEBOV vaccine to assess ZEBOV glycoprotein (IgG) antibody persistence. The primary outcome was ZEBOV glycoprotein-specific IgG geometric mean concentrations (GMCs) measured yearly by ELISA compared with 1 month (ie, 28 days) after immunisation. We report GMCs up to 2 years (Geneva, Switzerland, including neutralising antibodies up to 6 months) and 1 year (Lambaréné, Gabon; Kilifi, Kenya) after vaccination and factors associated with higher antibody persistence beyond 6 months, according to multivariable analyses. Trials and the observational study were registered at ClinicalTrials.gov (Geneva: NCT02287480 and NCT02933931; Kilifi: NCT02296983) and the Pan-African Clinical Trials Registry (Lambaréné PACTR201411000919191). FINDINGS: Of 217 vaccinees from the original studies (102 from the Geneva study, 75 from the Lambaréné study, and 40 from the Kilifi study), 197 returned and provided samples at 1 year (95 from the Geneva study, 63 from the Lambaréné, and 39 from the Kilifi study) and 90 at 2 years (all from the Geneva study). In the Geneva group, 44 (100%) of 44 participants who had been given a high dose (ie, 10-50 million pfu) of vaccine and who were seropositive at day 28 remained seropositive at 2 years, whereas 33 (89%) of 37 who had been given the low dose (ie, 300 000 pfu) remained seropositive for 2 years (p=0·042). In participants who had received a high dose, ZEBOV glycoprotein IgG GMCs decreased significantly between their peak (at 1-3 months) and month 6 after vaccination in Geneva (p<0·0001) and Lambaréné (p=0·0298) but not in Kilifi (p=0·5833) and subsequently remained stable at all sites apart from Geneva, where GMC in those given a high dose of vaccine increased significantly between 6 months and 1 year (p=0·0264). Antibody persistence was similar at 1 year and at 6 months in those who had received a low dose of vaccine, with lower titres among participants from the Geneva study at 2 years than at 1 year after vaccination (GMC ratio 0·61, 95% CI 0·49-0·77; p<0·0001). In multivariable analyses, predictors of increased IgG GMCs beyond 6 months included high-dose versus low-dose vaccination (Geneva p=0·0133; Lambaréné p=0·008) and vaccine-related arthritis (p=0·0176), but not sex, age, or baseline seropositivity (all p>0·05). Neutralising antibodies seem to be less durable, with seropositivity dropping from 64-71% at 28 days to 27-31% at 6 months in participants from the Geneva study. INTERPRETATION: Antibody responses to single-dose rVSV-ZEBOV vaccination are sustained across dose ranges and settings, a key criterion in countries where booster vaccinations would be impractical. FUNDING: The Wellcome Trust and Innovative Medicines Initiative 2 Joint Undertaking.
Authors: John M Dye; Andrew S Herbert; Ana I Kuehne; James F Barth; Majidat A Muhammad; Samantha E Zak; Ramon A Ortiz; Laura I Prugar; William D Pratt Journal: Proc Natl Acad Sci U S A Date: 2012-03-12 Impact factor: 11.205
Authors: Dennis D Taub; William B Ershler; Mark Janowski; Andrew Artz; Michael L Key; Julie McKelvey; Denis Muller; Bernard Moss; Luigi Ferrucci; Patricia L Duffey; Dan L Longo Journal: Am J Med Date: 2008-12 Impact factor: 4.965
Authors: Angela Huttner; Christophe Combescure; Stéphane Grillet; Mariëlle C Haks; Edwin Quinten; Christine Modoux; Selidji Todagbe Agnandji; Jessica Brosnahan; Julie-Anne Dayer; Ali M Harandi; Laurent Kaiser; Donata Medaglini; Tom Monath; Pascale Roux-Lombard; Peter G Kremsner; Tom H M Ottenhoff; Claire-Anne Siegrist Journal: Sci Transl Med Date: 2017-04-12 Impact factor: 17.956
Authors: Ana Maria Henao-Restrepo; Anton Camacho; Ira M Longini; Conall H Watson; W John Edmunds; Matthias Egger; Miles W Carroll; Natalie E Dean; Ibrahima Diatta; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Pierre-Stéphane Gsell; Stefanie Hossmann; Sara Viksmoen Watle; Mandy Kader Kondé; Sakoba Kéïta; Souleymane Kone; Eewa Kuisma; Myron M Levine; Sema Mandal; Thomas Mauget; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; John-Arne Røttingen; Marie-Paule Kieny Journal: Lancet Date: 2016-12-23 Impact factor: 79.321
Authors: Moses J Soka; Mary J Choi; April Baller; Stephen White; Emerson Rogers; Lawrence J Purpura; Nuha Mahmoud; Christine Wasunna; Moses Massaquoi; Neetu Abad; Jomah Kollie; Straker Dweh; Philip K Bemah; Athalia Christie; Victor Ladele; Oneykachi C Subah; Satish Pillai; Margaret Mugisha; Jonathan Kpaka; Stephen Kowalewski; Emilio German; Mark Stenger; Stuart Nichol; Ute Ströher; Kristin E Vanderende; Shauna Mettee Zarecki; Hugh Henry W Green; Jeffrey A Bailey; Pierre Rollin; Barbara Marston; Tolbert G Nyenswah; Alex Gasasira; Barbara Knust; Desmond Williams Journal: Lancet Glob Health Date: 2016-08-30 Impact factor: 26.763
Authors: Chad R Wells; Abhishek Pandey; Alyssa S Parpia; Meagan C Fitzpatrick; Lauren A Meyers; Burton H Singer; Alison P Galvani Journal: Proc Natl Acad Sci U S A Date: 2019-04-29 Impact factor: 11.205
Authors: Barbara E Mahon; Jakub Simon; Marc-Alain Widdowson; Mohamed Samai; Eric Rogier; Jennifer Legardy-Williams; Kenneth Liu; Jarad Schiffer; James Lange; Carolynn DeByle; Robert Pinner; Anne Schuchat; Laurence Slutsker; Susan Goldstein Journal: J Infect Dis Date: 2021-12-01 Impact factor: 5.226
Authors: Shevin T Jacob; Ian Crozier; William A Fischer; Angela Hewlett; Colleen S Kraft; Marc-Antoine de La Vega; Moses J Soka; Victoria Wahl; Anthony Griffiths; Laura Bollinger; Jens H Kuhn Journal: Nat Rev Dis Primers Date: 2020-02-20 Impact factor: 52.329
Authors: Dominic Paquin-Proulx; Bronwyn M Gunn; Aljawharah Alrubayyi; Danielle V Clark; Matthew Creegan; Dohoon Kim; Hannah Kibuuka; Monica Millard; Salim Wakabi; Leigh Anne Eller; Nelson L Michael; Randal J Schoepp; Matthew J Hepburn; Lisa E Hensley; Merlin L Robb; Galit Alter; Michael A Eller Journal: Front Immunol Date: 2021-05-20 Impact factor: 7.561
Authors: Pavlo Gilchuk; Adrian Guthals; Stefano R Bonissone; Jared B Shaw; Philipp A Ilinykh; Kai Huang; Robin G Bombardi; Jenny Liang; Ariadna Grinyo; Edgar Davidson; Elaine C Chen; Bronwyn M Gunn; Galit Alter; Erica Ollmann Saphire; Benjamin J Doranz; Alexander Bukreyev; Larry Zeitlin; Natalie Castellana; James E Crowe Journal: Front Immunol Date: 2021-07-16 Impact factor: 7.561